Saturday, October 31, 2026

Estee Lauder Companies Stock Is 16% Down So Far On Wednesday

Estee Lauder Companies Stock Is 16% Down So Far On Wednesday

(VIANEWS) - Shares of Estee Lauder Companies (NYSE: EL) slid by a staggering 16.65% to $204.38 at 11:49 EST on Wednesday, following the last session's downward trend. NYSE is jumping 0.02% to $15,317.00, after two consecutive sessions in a row of losses. This seems, so far, a somewhat up trend trading session today.

Estee Lauder Companies's last close was $245.22, 13.79% below its 52-week high of $284.45.

About Estee Lauder Companies

The Estée Lauder Companies Inc. manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide. It offers a range of skin care products, including moisturizers, serums, cleansers, toners, body care, exfoliators, acne care and oil correctors, facial masks, cleansing devices, and sun care products; and makeup products, such as lipsticks, lip glosses, mascaras, foundations, eyeshadows, nail polishes, and powders, as well as compacts, brushes, and other makeup tools. The company also provides fragrance products in various forms comprising eau de parfum sprays and colognes, as well as lotions, powders, creams, candles, and soaps; and hair care products that include shampoos, conditioners, styling products, treatment, finishing sprays, and hair color products, as well as sells ancillary products and services. It offers its products under the Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, Bobbi Brown, La Mer, Aveda, Jo Malone London, Bumble and bumble, Darphin, Smashbox, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr. Jart+, DECIEM, and The Ordinary brands. The company sells its products through department stores, specialty-multi retailers, upscale perfumeries and pharmacies, and salons and spas; freestanding stores; its own and authorized retailer websites; third-party online malls; stores in airports; and duty-free shops. The Estée Lauder Companies Inc. was founded in 1946 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, Estee Lauder Companies has a trailing twelve months EPS of $4.15.

PE Ratio

Estee Lauder Companies has a trailing twelve months price to earnings ratio of 49.25. Meaning, the purchaser of the share is investing $49.25 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.86%.

Yearly Top and Bottom Value

Estee Lauder Companies's stock is valued at $204.38 at 11:49 EST, way under its 52-week high of $284.45 and higher than its 52-week low of $186.47.

Revenue Growth

Year-on-year quarterly revenue growth declined by 16.6%, now sitting on 16.36B for the twelve trailing months.

Volume

Today's last reported volume for Estee Lauder Companies is 7298895 which is 444.71% above its average volume of 1339940.

Moving Average

Estee Lauder Companies's value is way below its 50-day moving average of $245.44 and way under its 200-day moving average of $244.32.

More news about Estee Lauder Companies (EL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com